|
|
News Breaks | | | | January 6, 2012 | | 08:10 EDT |  | ITMN | InterMune a top 2012 pick, says Brean Murray
Brean Murray said negative macro and company specific catalysts created a buying opportunity for InterMune. The firm called it a top pick for 2012 citing valuation, implications for strong German demand of Esbriet, and the orphan drug status of the drug. Shares are Buy rated with a $42 price target. | |
|
News For ITMN From The Last 14 Days Check below for free stories on ITMN the last two weeks. |
|
|
| There are no results for ITMN |
|
|
|
|
|
|
